Please Wait.....
Report
Nanomedicine Market Research Report Forecast to 2032
Market Report I 2024-11-21 I 149 Pages I Market Research Future
Nanomedicine Market Research Report: Information by Modality (Treatments and Diagnostics), by Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, and Implants), and by Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Diseases, Neurological Diseases, Urological Diseases, Ophthalmological Diseases, Immunological Diseases, and Others), by Molecule Type (Nanoparticles [Albumin Particles, Inorganic Nanoparticles, Lipid Nanoparticle, Liposomes, and Others], Nanoshells, Nanotubes, and Nanodevices), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032
Market Overview
In 2023, the nanomedicine market was estimated to be worth USD 252.97 billion. During the forecast period (2024-2032), the Nanomedicine Market industry is anticipated to experience a compound annual growth rate (CAGR) of 12.48%, increasing from USD 273.79 billion in 2024 to USD 819.84 billion by 2032.
The global market is experiencing growth due to the increasing prevalence of a variety of diseases worldwide and the agreements that are associated with the development of nanomedicine products.
Market segment insights
The Nanomedicine Market has been divided into treatments and diagnostics based on modality.
The Nanomedicine Market has been segmented into the following categories: drug delivery, diagnostic imaging, vaccines, regenerative medicine, and implants.
The Nanomedicine Market has been segmented into oncological diseases, infectious diseases, cardiovascular diseases, orthopedic diseases, neurological diseases, urological diseases, ophthalmological diseases, immunological diseases, and others, based on indication.
The Nanomedicine Market has been segmented into nanoparticles, nanoshells, nanotubes, and nanodevices based on the type of molecule.
Regional Perspectives
The market is segmented into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. North America held the largest market share of over 38.14% in 2023, which was attributed to the robust research and development infrastructure and the growing prevalence of cancer incidence. For example, in 2020, the United States reported 1,603,844 new cancer cases and 602,347 cancer fatalities. There were 403 new cancer cases reported per 100,000 individuals, and 144 individuals passed away from cancer.
The market for nanomedicine in Europe is rapidly expanding as a result of the potential to revolutionize healthcare and the advancements in nanotechnology. This market encompasses the development and utilization of nanoscale materials and devices for the purposes of diagnosis, therapy, and monitoring. The market is expanding as a result of the increasing demand for personalized treatment and the increasing prevalence of chronic diseases. Europe is at the forefront of nanomedicine advancements as a result of its robust healthcare infrastructure and substantial research and development expenditures. Nanoscale imaging techniques, targeted drug delivery methods, and enhanced cancer therapeutics are critical areas of emphasis.
The Asia-Pacific nanomedicine market is a reflection of the increasing interest and investment in advanced healthcare technologies in the region, which is characterized by its rapid evolution. The market is anticipated to experience rapid growth as a result of a variety of factors, such as the increasing prevalence of chronic ailments, the necessity for additional healthcare, and significant advancements in nanotechnology research.
Major Players
Sanofi (France), Johnson & Johnson Services, Inc. (US), Parvus Therapeutics Inc. (US), Nanobiotix (France), Ascendia Pharmaceuticals (US), Bristol-Myers Squibb Company (US), Jazz Pharmaceuticals (Ireland), Cytimmune Sciences, Inc. (US), Nanospectra Biosciences (US), and Pfizer, Inc. (US) are among the key companies in the nanomedicine market.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING INCIDENCES OF VARIOUS DISEASES ACROSS THE GLOBE
4.2.2 AGREEMENTS ASSOCIATED WITH NANOMEDICINE PRODUCTS DEVELOPMENTS
4.3 RESTRAINTS
4.3.1 HIGH MANUFACTURING COST OF NANOMEDICINE
4.4 OPPORTUNITY
4.4.1 INCREASING NUMBER OF PIPELINE PRODUCTS
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL NANOMEDICINE MARKET
6 GLOBAL NANOMEDICINE MARKET, BY MODALITY
6.1 OVERVIEW
6.2 TREATMENTS
6.3 DIAGNOSTICS
7 GLOBAL NANOMEDICINE MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 DRUG DELIVERY
7.3 DIAGNOSTIC IMAGING
7.4 VACCINES
7.5 REGENERATIVE MEDICINE
7.6 IMPLANTS
8 GLOBAL NANOMEDICINE MARKET, BY INDICATION
8.1 OVERVIEW
8.2 ONCOLOGICAL DISEASES
8.3 INFECTIOUS DISEASES
8.4 CARDIOVASCULAR DISEASES
8.5 ORTHOPEDIC DISEASES
8.6 NEUROLOGICAL DISEASES
8.7 UROLOGICAL DISEASES
8.8 OPHTHALMOLOGICAL DISEASES
8.9 IMMUNOLOGICAL DISEASES
8.10 OTHERS
9 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE
9.1 OVERVIEW
9.2 NANOPARTICLES
9.3 NANOSHELLS
9.4 NANOTUBES
9.5 NANODEVICES
9.5.1 ALBUMIN PARTICLES
9.5.2 INORGANIC NANOPARTICLES
9.5.3 LIPID NANOPARTICLE
9.5.4 LIPOSOMES
9.5.5 OTHERS
10 GLOBAL NANOMEDICINE MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2023
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
11.6.2 PARTNERSHIP/AGREEMENT/COLLABORATION
12 COMPANY PROFILES
12.1 SANOFI
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 JOHNSON & JOHNSON SERVICES, INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGY
12.3 PARVUS THERAPEUTICS INC.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 NANOBIOTIX
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGY
12.5 ASCENDIA PHARMACEUTICAL
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGY
12.6 BRISTOL-MYERS SQUIBB COMPANY
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 JAZZ PHARMACEUTICALS
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 CYTIMMUNE SCIENCES, INC.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 NANOSPECTRA BIOSCIENCES
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 PFIZER INC
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
13 DATA CITATIONS
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL NANOMEDICINE MARKET, FOR TREATMENTS, BY REGION, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL NANOMEDICINE MARKET, FOR DIAGNOSTICS, BY REGION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL NANOMEDICINE MARKET, FOR DRUG DELIVERY, BY REGION, 2019-2032 (USD BILLION)
TABLE 7 GLOBAL NANOMEDICINE MARKET, FOR DIAGNOSTIC IMAGING, BY REGION, 2019-2032 (USD BILLION)
TABLE 8 GLOBAL NANOMEDICINE MARKET, FOR VACCINES, BY REGION, 2019-2032 (USD BILLION)
TABLE 9 GLOBAL NANOMEDICINE MARKET, FOR REGENERATIVE MEDICINE, BY REGION, 2019-2032 (USD BILLION)
TABLE 10 GLOBAL NANOMEDICINE MARKET, FOR IMPLANTS, BY REGION, 2019-2032 (USD BILLION)
TABLE 11 GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 12 GLOBAL NANOMEDICINE MARKET, FOR ONCOLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 13 GLOBAL NANOMEDICINE MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 14 GLOBAL NANOMEDICINE MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 15 GLOBAL NANOMEDICINE MARKET, FOR ORTHOPEDIC DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 16 GLOBAL NANOMEDICINE MARKET, FOR NEUROLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 17 GLOBAL NANOMEDICINE MARKET, FOR UROLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 18 GLOBAL NANOMEDICINE MARKET, FOR OPHTHALMOLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 19 GLOBAL NANOMEDICINE MARKET, FOR IMMUNOLOGICAL DISEASES, BY REGION, 2019-2032 (USD BILLION)
TABLE 20 GLOBAL NANOMEDICINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 21 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 22 GLOBAL NANOMEDICINE MARKET, FOR NANOPARTICLES, BY REGION, 2019-2032 (USD BILLION)
TABLE 23 GLOBAL NANOMEDICINE MARKET, FOR NANOSHELLS, BY REGION, 2019-2032 (USD BILLION)
TABLE 24 GLOBAL NANOMEDICINE MARKET, FOR NANOTUBES, BY REGION, 2019-2032 (USD BILLION)
TABLE 25 GLOBAL NANOMEDICINE MARKET, FOR NANODEVICES, BY REGION, 2019-2032 (USD BILLION)
TABLE 26 GLOBAL NANOMEDICINE MARKET, FOR NANODEVICES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 27 GLOBAL NANOMEDICINE MARKET, FOR ALBUMIN PARTICLES, BY REGION, 2019-2032 (USD BILLION)
TABLE 28 GLOBAL NANOMEDICINE MARKET, FOR INORGANIC NANOPARTICLES, BY REGION, 2019-2032 (USD BILLION)
TABLE 29 GLOBAL NANOMEDICINE MARKET, FOR LIPID NANOPARTICLE, BY REGION, 2019-2032 (USD BILLION)
TABLE 30 GLOBAL NANOMEDICINE MARKET, FOR LIPOSOMES, BY REGION, 2019-2032 (USD BILLION)
TABLE 31 GLOBAL NANOMEDICINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 32 GLOBAL NANOMEDICINE MARKET, BY REGION, 2019-2032 (USD BILLION)
TABLE 33 NORTH AMERICA: NANOMEDICINE MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 34 NORTH AMERICA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 35 NORTH AMERICA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 36 NORTH AMERICA: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 37 NORTH AMERICA: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 38 NORTH AMERICA: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 39 US: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 40 US: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 41 US: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 42 US: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 43 US: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 44 CANADA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 45 CANADA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 46 CANADA: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 47 US: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 48 CANADA: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 49 EUROPE: NANOMEDICINE MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 50 EUROPE: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 51 EUROPE: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 52 EUROPE: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 53 EUROPE: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 54 EUROPE: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 55 GERMANY: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 56 GERMANY: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 57 GERMANY: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 58 GERMANY: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 59 GERMANY: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 60 FRANCE: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 61 FRANCE: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 62 FRANCE: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 63 FRANCE: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 64 FRANCE: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 65 UK: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 66 UK: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 67 UK: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 68 UK: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 69 UK: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 70 ITALY: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 71 ITALY: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 72 ITALY: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 73 ITALY: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 74 ITALY: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 75 SPAIN: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 76 SPAIN: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 77 SPAIN: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 78 SPAIN: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 79 SPAIN: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 80 REST OF EUROPE: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 81 REST OF EUROPE: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 82 REST OF EUROPE: NANOMEDICINE MARKET, FOR INDICATION, 2019-2032 (USD BILLION)
TABLE 83 REST OF EUROPE: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 84 REST OF EUROPE: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019-2032 (USD BILLION)
TABLE 85 ASIA-PACIFIC: NANOMEDICINE MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 86 ASIA-PACIFIC: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 87 ASIA-PACIFIC: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 88 ASIA-PACIFIC: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 89 ASIA-PACIFIC: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 90 ASIA-PACIFIC: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 91 CHINA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 92 CHINA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 93 CHINA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 94 CHINA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 95 CHINA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 96 INDIA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 97 INDIA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 98 INDIA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 99 INDIA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 100 INDIA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 101 JAPAN: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 102 JAPAN: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 103 JAPAN: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 104 JAPAN: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 105 JAPAN: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 106 SOUTH KOREA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 107 SOUTH KOREA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 108 SOUTH KOREA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 109 SOUTH KOREA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 110 SOUTH KOREA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 111 AUSTRALIA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 112 AUSTRALIA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 113 AUSTRALIA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 114 AUSTRALIA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 115 AUSTRALIA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 116 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 117 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 118 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 119 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 120 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 121 REST OF THE WORLD: NANOMEDICINE MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 122 REST OF THE WORLD: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 123 REST OF THE WORLD: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 124 REST OF THE WORLD: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 125 REST OF THE WORLD: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 126 REST OF THE WORLD: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 127 MIDDLE EAST: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 128 MIDDLE EAST: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 129 MIDDLE EAST: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 130 MIDDLE EAST: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 131 MIDDLE EAST: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 132 AFRICA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 133 AFRICA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 134 AFRICA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 135 AFRICA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 136 AFRICA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 137 LATIN AMERICA: NANOMEDICINE MARKET, BY MODALITY, 2019-2032 (USD BILLION)
TABLE 138 LATIN AMERICA: NANOMEDICINE MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 139 LATIN AMERICA: NANOMEDICINE MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 140 LATIN AMERICA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019-2032 (USD BILLION)
TABLE 141 LATIN AMERICA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019-2032 (USD BILLION)
TABLE 142 PUBLIC PLAYERS STOCK SUMMARY
TABLE 143 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 144 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 145 PARTNERSHIP/AGREEMENT/COLLABORATION
TABLE 146 SANOFI: PRODUCTS OFFERED
TABLE 147 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
TABLE 148 PARVUS THERAPEUTICS INC.: PRODUCT OFFERED
TABLE 149 PARVUS THERAPEUTICS INC. KEY DEVELOPMENTS
TABLE 150 NANOBIOTIX: PRODUCTS OFFERED
TABLE 151 NANOBIOTIX: KEY DEVELOPMENTS
TABLE 152 ASCENDIA PHARMACEUTICAL: PRODUCTS OFFERED
TABLE 153 ASCENDIA PHARMACEUTICALS: KEY DEVELOPMENTS
TABLE 154 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
TABLE 155 JAZZ PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 156 CYTIMMUNE SCIENCES, INC.: PRODUCTS OFFERED
TABLE 157 CYTIMMUNE SCIENCES, INC.: KEY DEVELOPMENTS
TABLE 158 NANOSPECTRA BIOSCIENCES: PRODCUTS OFFERED
TABLE 159 PFIZER INC: PRODUCT OFFERED
TABLE 160 PFIZER INC: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL NANOMEDICINE MARKET: STRUCTURE
FIGURE 2 GLOBAL NANOMEDICINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL NANOMEDICINE MARKET
FIGURE 6 GLOBAL NANOMEDICINE MARKET, MODALITY SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)
FIGURE 7 GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2023 & 2032 (USD BILLION)
FIGURE 8 GLOBAL NANOMEDICINE MARKET SHARE (%), BY MODALITY, 2023
FIGURE 9 GLOBAL NANOMEDICINE MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)
FIGURE 10 GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2023 & 2032 (USD BILLION)
FIGURE 11 GLOBAL NANOMEDICINE MARKET SHARE (%), BY APPLICATION, 2023
FIGURE 12 GLOBAL NANOMEDICINE MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)
FIGURE 13 GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2023 & 2032 (USD BILLION)
FIGURE 14 GLOBAL NANOMEDICINE MARKET SHARE (%), BY INDICATION, 2023
FIGURE 15 GLOBAL NANOMEDICINE MARKET, MOLECULE TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)
FIGURE 16 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE, 2023 & 2032 (USD BILLION)
FIGURE 17 GLOBAL NANOMEDICINE MARKET SHARE (%), BY MOLECULE TYPE, 2023
FIGURE 18 GLOBAL NANOMEDICINE MARKET, BY REGION, 2023 & 2032 (USD BILLION)
FIGURE 19 GLOBAL NANOMEDICINE MARKET SHARE, BY REGION, 2023 (% SHARE)
FIGURE 20 NORTH AMERICA MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)
FIGURE 21 NORTH AMERICA NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)
FIGURE 22 NORTH AMERICA NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 23 EUROPE MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)
FIGURE 24 EUROPE NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)
FIGURE 25 EUROPE NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)
FIGURE 27 ASIA-PACIFIC NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)
FIGURE 28 ASIA-PACIFIC NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)
FIGURE 30 REST OF THE WORLD NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)
FIGURE 31 REST OF THE WORLD NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 1 NANOMEDICINE MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
FIGURE 2 COMPETITOR DASHBOARD: NANOMEDICINE MARKET
FIGURE 3 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 4 SANOFI: SWOT ANALYSIS
FIGURE 5 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 6 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS
FIGURE 7 NANOBIOTIX: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 8 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 9 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS
FIGURE 10 JAZZ PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 11 JAZZ PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 12 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 PFIZER INC: SWOT ANALYSIS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security